Results For "JP-Morgan"

3 News Found

Biocon Biologics unveils three new oncology biosimilars, eyes $75 billion market opportunity

News | January 08, 2026

Biocon Biologics unveils three new oncology biosimilars, eyes $75 billion market opportunity

The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies

Aster DM Healthcare promoters reduce share pledge from 99% to 41%

News | March 12, 2025

Aster DM Healthcare promoters reduce share pledge from 99% to 41%

The new lenders – JP Morgan, HSBC, and Barclays provided fresh funding

Fortis Healthcare appoints Leo Puri as Chairman of the Board

People | December 28, 2024

Fortis Healthcare appoints Leo Puri as Chairman of the Board

Puri is an accomplished leader and financial sector veteran with over four decades of experience

Latest Stories

Lilly to buy Ventyx Biosciences for $1.2 billion

Amgen snaps up UK biotech Dark Blue Therapeutics in up to $840m oncology deal

Biocon Biologics unveils three new oncology biosimilars, eyes $75 billion market opportunity

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging